Comparison
While Exenatide is used for type 2 diabetes treatment to improve glycemic control and modestly reduce body weight through GLP-1–like insulinotropic and glucagonostatic effects6768, Semaglutide is approved for type 2 diabetes and chronic weight management, significantly lowering HbA1c and body weight by modulating incretin pathways232480.
While Exenatide works as a 39-amino-acid exendin-4 peptide originally isolated from Gila monster venom that acts as a long-acting GLP-1 receptor agonist resistant to DPP-4 degradation67, Semaglutide is a modified GLP-1(7–37) analog with three key changes—Ala8→Aib, Lys26 acylated with a C18 fatty diacid, and Lys34→Arg—resulting in a long-acting GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite23647480.
Exenatide is 39 amino acids long, whereas Semaglutide is shorter as it has a length of 31 amino acids. Exenatide is made up of a sequence of sequence data not available in the current dataset. Semaglutide is made up of a sequence of sequence data not available in the current dataset.
Exenatide
Not assigned in the current dataset.
Semaglutide
GCG